Quetiapine augmentation for depression: dosing pattern in routine practice
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pae, Chi-Un | - |
dc.contributor.author | Wang, Sheng-Min | - |
dc.contributor.author | Han, Changsu | - |
dc.contributor.author | Lee, Soo-Jung | - |
dc.contributor.author | Patkar, Ashwin A. | - |
dc.contributor.author | Masand, Prakash S. | - |
dc.date.accessioned | 2021-09-04T20:31:21Z | - |
dc.date.available | 2021-09-04T20:31:21Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2015-01 | - |
dc.identifier.issn | 0268-1315 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/94794 | - |
dc.description.abstract | This study investigated the dosing patterns of quetiapine augmentation (QA) for major depressive disorder (MDD) in routine practice. Between 1 January 2009 and 31 May 2013, patients with a diagnosis of MDD who were receiving QA in conjunction with an ongoing antidepressant were recruited into this study. The electronic medical records and clinical data for a total of 977 patients were reviewed up to a year. Almost half the patients maintained QA treatment for more than 3 months. The mean duration of QA was similar to 6 months, and the mean initial and maintenance doses were 23.6 and 40.7 mg/day, respectively (range=12.5-400 mg/day). The most frequent adverse events observed were somnolence, followed by dry mouth and lethargy. Our results indicate that the actual doses of QA for MDD in routine practice should be lower than the doses used in placebo-controlled clinical trials and those recommended by a regulatory agency. Adequately powered and well-controlled prospective studies are needed to better understand the exact role of low doses of QA in the treatment of MDD, particularly in routine practice. (C) 2014 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.subject | EXTENDED-RELEASE QUETIAPINE | - |
dc.subject | LOW-DOSE ARIPIPRAZOLE | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | ANTIDEPRESSANT TREATMENT | - |
dc.subject | INADEQUATE RESPONSE | - |
dc.subject | CLINICAL-PRACTICE | - |
dc.subject | POOLED ANALYSIS | - |
dc.subject | DISORDER | - |
dc.subject | PLACEBO | - |
dc.subject | FUMARATE | - |
dc.title | Quetiapine augmentation for depression: dosing pattern in routine practice | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Han, Changsu | - |
dc.identifier.doi | 10.1097/YIC.0000000000000055 | - |
dc.identifier.scopusid | 2-s2.0-84918780345 | - |
dc.identifier.wosid | 000345921900009 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, v.30, no.1, pp.54 - 58 | - |
dc.relation.isPartOf | INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY | - |
dc.citation.title | INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY | - |
dc.citation.volume | 30 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 54 | - |
dc.citation.endPage | 58 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.subject.keywordPlus | EXTENDED-RELEASE QUETIAPINE | - |
dc.subject.keywordPlus | LOW-DOSE ARIPIPRAZOLE | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | ANTIDEPRESSANT TREATMENT | - |
dc.subject.keywordPlus | INADEQUATE RESPONSE | - |
dc.subject.keywordPlus | CLINICAL-PRACTICE | - |
dc.subject.keywordPlus | POOLED ANALYSIS | - |
dc.subject.keywordPlus | DISORDER | - |
dc.subject.keywordPlus | PLACEBO | - |
dc.subject.keywordPlus | FUMARATE | - |
dc.subject.keywordAuthor | atypical antipsychotics | - |
dc.subject.keywordAuthor | augmentation | - |
dc.subject.keywordAuthor | doses | - |
dc.subject.keywordAuthor | major depressive disorder | - |
dc.subject.keywordAuthor | quetiapine | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.